Zacks Research Equities Analysts Decrease Earnings Estimates for Qiagen (NYSE:QGEN)

Qiagen (NYSE:QGEN) – Equities researchers at Zacks Research dropped their Q1 2025 earnings per share (EPS) estimates for shares of Qiagen in a report released on Monday, June 17th. Zacks Research analyst M. Mondal now expects that the company will post earnings per share of $0.47 for the quarter, down from their prior forecast of $0.48. The consensus estimate for Qiagen’s current full-year earnings is $2.14 per share. Zacks Research also issued estimates for Qiagen’s Q4 2025 earnings at $0.62 EPS.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Monday, April 29th. The company reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. The business had revenue of $459.00 million during the quarter, compared to analyst estimates of $453.91 million. Qiagen had a return on equity of 12.59% and a net margin of 17.38%. The company’s revenue was down 5.4% on a year-over-year basis. During the same quarter last year, the business posted $0.53 EPS.

QGEN has been the subject of several other research reports. JPMorgan Chase & Co. lifted their price target on Qiagen from $52.00 to $54.00 and gave the company an “overweight” rating in a research note on Tuesday. Stifel Nicolaus cut their price target on Qiagen from $55.00 to $45.00 and set a “hold” rating for the company in a research note on Wednesday, May 1st. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $51.17.

Qiagen Stock Performance

NYSE QGEN opened at $43.75 on Wednesday. The stock has a 50-day simple moving average of $43.01 and a two-hundred day simple moving average of $43.65. The firm has a market capitalization of $9.98 billion, a P/E ratio of 29.34, a PEG ratio of 3.61 and a beta of 0.42. Qiagen has a fifty-two week low of $34.74 and a fifty-two week high of $47.70. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.45 and a current ratio of 1.84.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Massachusetts Financial Services Co. MA boosted its holdings in shares of Qiagen by 8.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 24,066,569 shares of the company’s stock worth $1,045,211,000 after purchasing an additional 1,809,486 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Qiagen by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 8,815,467 shares of the company’s stock worth $382,856,000 after purchasing an additional 83,371 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Qiagen by 20.1% during the 4th quarter. Wellington Management Group LLP now owns 7,271,828 shares of the company’s stock worth $316,463,000 after purchasing an additional 1,217,712 shares during the last quarter. Norges Bank acquired a new position in shares of Qiagen during the 4th quarter worth approximately $264,322,000. Finally, FIL Ltd boosted its holdings in shares of Qiagen by 8.5% during the 4th quarter. FIL Ltd now owns 5,099,140 shares of the company’s stock worth $221,784,000 after purchasing an additional 399,965 shares during the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.